Johnson & Johnson Innovation - JJDC

Johnson & Johnson Innovation - JJDC, established in 1973 and based in New Brunswick, New Jersey, serves as the corporate venture capital arm of Johnson & Johnson. The organization focuses on accelerating early-stage innovation by fostering strategic collaborations. JJDC connects potential partners with essential resources to support advancements in transformation science and technology across various sectors, including pharmaceuticals, medical devices, consumer healthcare, and medtech. Through its investment activities, JJDC aims to drive innovation and enhance the development of new solutions that can improve health and well-being.

Kadir Kadhiresan Ph.D

Vice President, Venture Investments

Fiona MacLaughlin Ph.D

Principal, Venture Investments

Tamir Meiri

Principal, Venture Investments

Sanjay Mistry Ph.D

Vice President, Venture Investments, New Company Creation

Marian Nakada Ph.D

Vice President, Venture Investments

Asha Nayak Ph.D

Vice President, Consumer Health Investments

Hirak Parikh Ph.D

Principal, Venture Investments

Chris Picariello

President

Wei Wu Ph.D

Principal, Venture Investments

Elizabeth Wu Ph.D

Director, Early Innovation Partnering

Asish Xavier

Vice President, Venture Investments

105 past transactions

Prazer Therapeutics

Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design methodologies, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By focusing on areas of unmet medical need, Prazer Therapeutics aims to advance drug development and provide solutions for diseases that currently lack effective therapies.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

TECLens

Series A in 2025
TECLens designs and manufactures medical vision-correction devices centered on a corneal crosslinking lens for myopia treatment and related conditions. The core product is a non-invasive therapy worn for about 30 minutes in a clinician’s waiting room, with the eye open or closed, delivering real-time ultrasound sensing and precise prescription tuning to reshape the cornea. The lens operates in a high-oxygen environment and uses scleral positioning to maintain stability during treatment. It aims to address presbyopia, slow progression of myopia in children, and corrections for keratoconus and other refractive errors, potentially reducing long-term reliance on traditional corrective lenses. The company is based in St. James, New York.

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Citryll

Series B in 2024
Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

G.I. Windows

Series B in 2024
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

TRex Bio

Series B in 2024
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Orasis Pharmaceuticals

Series D in 2024
Orasis Pharmaceuticals Ltd is a pharmaceutical company based in Herzliya, Israel, founded in 2015. The company specializes in the development of corrective eye drops aimed at treating presbyopia, a common age-related vision condition. Its primary product, CSF-1, is designed to improve near visual acuity through pupil modulation, thereby alleviating the need for reading glasses. By repurposing existing, well-studied molecules, CSF-1 aims to provide an effective, safe, and easy-to-use solution that enhances the quality of life for individuals affected by presbyopia. This noninvasive treatment option offers patients a practical alternative for managing their near vision difficulties.

ONL Therapeutics

Series D in 2024
ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

SpectraWAVE

Series B in 2024
SpectraWAVE, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in the development and manufacturing of optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Its flagship product includes a spectroscopy catheter that assists in diagnosing and treating cardiovascular conditions. SpectraWAVE has also developed an advanced intravascular imaging technology that integrates proven imaging methodologies to improve outcomes for coronary artery disease. This technology provides interventional cardiologists with critical optical and computational insights to optimize stent interventions and identify patients and plaques at risk of adverse coronary events, ultimately aiming to improve patient treatment and outcomes in the field of cardiovascular health.

HistoSonics

Series D in 2024
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Loci Orthopaedics

Series A in 2024
Loci Orthopaedics Limited, established in 2017 and headquartered in Upper Newcastle, Ireland, specialises in the manufacture of medical instruments, notably the InDx implant. This innovative device is designed to mimic natural thumb joint motions and offers a less invasive surgical solution for patients with arthritis in their thumb base joint, addressing a significant unmet clinical need in orthopaedics.

Asceneuron

Series C in 2024
Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

Bright Peak Therapeutics

Series C in 2024
Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Neuroene Therapeutics

Grant in 2024
Neuroene Therapeutics is a startup biotechnology company developing novel Vitamin K-based therapeutics for neurological disorders such as epilepsy. The company originated from collaborative research between Medical University of South Carolina investigators C. James Chou, Ph.D., and Sherine Chan, Ph.D., who cofounded and continue to lead Neuroene Therapeutics.

Flindr Therapeutics

Series A in 2024
Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.

Rallybio

Post in 2024
Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Tempo Therapeutics

Series A in 2024
Tempo Therapeutics is a life science company focused on advancing regenerative medicine through innovative materials and immunomodulation. The company develops precision-engineered, minimally invasive hydrogels that utilize cell-free synthetic materials and geometric technology. These materials are designed to evade the body's immune rejection responses, facilitating the creation of synthetic tissue hybrids across various organs, including skin, bone, heart, and brain. By harnessing the body's regenerative capacity and controlling inflammation, Tempo Therapeutics aims to accelerate healing rates, reduce chronic tissue inflammation, and enhance overall regenerative healing in patients.

Asgard Therapeutics

Series A in 2024
Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Accent Therapeutics

Series C in 2024
Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Aro Biotherapeutics

Series B in 2023
Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

On Target Laboratories

Series C in 2023
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

RefleXion Medical

Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Jurata Thin Film

Grant in 2023
Jurata Thin Film specializes in innovative storage technology for vaccines and biologics, focusing on enhancing the manufacturing, distribution, and delivery processes. The company has developed a unique thin film matrix that stabilizes biological materials, including bacterial-based vaccines and antibody-based therapeutics. This technology allows for the long-term storage of these products at room temperature or higher, ensuring their therapeutic efficacy even in extreme conditions. The thin film can be rehydrated to recover the therapeutic payload in an aqueous solution, facilitating diverse delivery routes. By simplifying the complexities associated with vaccine and biologic storage, Jurata Thin Film aims to improve accessibility and reliability in the healthcare sector.

ROME Therapeutics

Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Arialys Therapeutics

Seed Round in 2023
Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Rapport Therapeutics

Series B in 2023
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

CirCode

Series A in 2023
CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Circular Code Biology

Series A in 2023
Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

Astraveus

Seed Round in 2023
Astraveus is a pioneering company specializing in the manufacture of Cell & Gene Therapies (CGTs). It operates the Lakhesys™ platform, an innovative end-to-end solution that optimizes CGT production using single-use microfluidic bioprocessors. This approach reduces infrastructure requirements, lowers costs, and mitigates logistical challenges, aiming to enhance patient access to life-changing therapies while minimizing environmental impact.

Solenic Medical

Series A in 2023
Solenic Medical, Inc. is a medical device company that focuses on developing a non-invasive treatment for infected metallic implants. Founded in 2019 and based in College Station, Texas, the company employs alternating magnetic fields generated from external coils to eliminate biofilm on the surfaces of these implants. This innovative technology aims to address significant complications that arise from surgeries, including knee and hip replacements, as well as in trauma-related implants such as plates and rods. Solenic Medical's approach offers the potential to replace the costly and risk-laden two-step revision surgical procedure currently used to manage chronic infections in medical implants.

Rapport Therapeutics

Series A in 2023
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages advanced protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By employing multiple therapeutic modalities, Perceive Biotherapeutics aims to provide medical professionals with effective solutions for preventing vision loss and enhancing patient outcomes in the field of ophthalmology.

HistoSonics

Convertible Note in 2022
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Pulmocide

Series C in 2022
Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

SonoThera

Series A in 2022
SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

DocSpera

Series B in 2022
DocSpera is an integrated surgical coordination platform that enhances synchronization across multiple sites and teams, ultimately improving workflow efficiencies and patient care. The company's proprietary platform automates pre-surgical coordination and facilitates real-time, secure synchronization of cases and images among key stakeholders, including surgeons, care teams, and device suppliers, utilizing electronic health record data. Additionally, DocSpera's intelligent surgical planning capabilities allow for continuous patient monitoring from the surgical decision phase through recovery, providing real-time insights and operating room dashboards to support physicians in their decision-making processes. Headquartered in Sunnyvale, California, DocSpera operates under Compliant Innovations Inc.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

TRex Bio

Series A in 2022
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Rondo Therapeutics

Series A in 2022
Rondo Therapeutics is a biopharmaceutical company based in Hayward, California, specializing in the discovery and development of innovative bispecific antibodies aimed at activating the immune system to combat cancer. Founded in 2021, the company focuses on creating cancer immunotherapies specifically for solid tumor types that do not respond to existing immune checkpoint inhibitors. By addressing areas of unmet medical need, Rondo Therapeutics aims to advance novel therapeutic options for patients facing challenging cancer diagnoses.

Iterative Scopes

Series B in 2022
Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

V-Wave

Series C in 2021
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

AviadoBio

Series A in 2021
AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Mauna Kea Technologies

Post in 2021
Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of advanced imaging technology for the diagnosis and treatment of cancers and other diseases. Founded in 2000, the company focuses on real-time in vivo microscopic visualization to eliminate uncertainties in medical diagnoses. Its primary product, Cellvizio, is a multidisciplinary confocal laser endomicroscopy platform that enables physicians to obtain cellular-level images of tissues during standard medical procedures. Cellvizio has received regulatory approval for use in the United States and over 40 other countries, supporting a wide range of applications. Mauna Kea Technologies generates revenue through the sale of Cellvizio devices, accessories, and related services, while emphasizing its role in enhancing diagnostic accuracy and informing therapeutic decisions.

Calypso Biotech

Series A in 2021
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.

FlexDex

Venture Round in 2021
FlexDex Inc. is a medical device company specializing in minimally invasive surgery (MIS) technology. Founded in 2010 and headquartered in Brighton, Michigan, the company has developed a platform that translates a surgeon's hand, wrist, and arm movements from outside the patient into precise movements of an end-effector inside the body. This innovative approach enhances the capabilities of MIS instruments and endoscopes, providing healthcare professionals with improved dexterity and control during surgical procedures. FlexDex serves its market through a network of distributors both in the United States and internationally.

Visus Therapeutics

Debt Financing in 2021
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals worldwide. The company is known for its presbyopia-correcting eye drops, which are designed to provide a prolonged solution to the loss of near vision associated with presbyopia. In addition to these eye drops, Visus Therapeutics is exploring various ophthalmic product candidates that address conditions such as ocular surface disease, glaucoma, and age-related macular degeneration, thereby broadening its impact on eye health and vision improvement.

Iterative Scopes

Series A in 2021
Iterative Scopes, Inc. is a Boston-based company established in 2017 that specializes in developing machine learning-powered diagnostic tools aimed at assisting gastroenterologists in the prevention of colon cancer. The company focuses on providing innovative solutions for physicians and life sciences professionals within the colorectal cancer and inflammatory bowel disease sectors. By leveraging advanced technology, Iterative Scopes aims to enhance diagnostic accuracy and improve patient outcomes in these critical areas of healthcare.

Point Biopharma Global

Post in 2021
Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Ribon Therapeutics

Series C in 2021
Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Thirty Madison

Series C in 2021
Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Pulmocide

Series C in 2021
Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Cue

Private Equity Round in 2021
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Mestag Therapeutics

Seed Round in 2021
Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

Sunday2Sunday

Series A in 2021
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.

Visus Therapeutics

Series A in 2021
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals worldwide. The company is known for its presbyopia-correcting eye drops, which are designed to provide a prolonged solution to the loss of near vision associated with presbyopia. In addition to these eye drops, Visus Therapeutics is exploring various ophthalmic product candidates that address conditions such as ocular surface disease, glaucoma, and age-related macular degeneration, thereby broadening its impact on eye health and vision improvement.

TechsoMed

Series B in 2021
TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Paige

Series C in 2021
Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.

ONL Therapeutics

Series B in 2020
ONL Therapeutics is a biopharmaceutical company headquartered in Ann Arbor, Michigan, that develops small‑molecule peptide therapeutics to protect photoreceptors and preserve vision. Its pipeline focuses on targeting the FAS apoptotic pathway to prevent photoreceptor loss in retinal diseases such as retinal detachment, aiming to improve surgical outcomes and reduce vision loss. Founded in 2006, the company seeks to bring novel treatments for serious, vision‑threatening retinal conditions.

Taza Aya

Grant in 2020
Taza Aya, headquartered in Ann Arbor, Michigan, is a technology company specializing in non-thermal plasma solutions. It develops and deploys innovative, non-thermal plasma technologies to neutralize airborne pathogens, enhancing air quality and safety in various industries. The company's primary focus is on creating a wearable device that integrates into building-scale HVAC systems, aiming to improve respiratory protection and comfort in workplaces and public spaces.

Datavant

Series B in 2020
Datavant is a health data platform company focused on securely connecting and organizing biomedical data to support drug development and clinical trials. It provides a privacy-preserving network that enables the secure exchange of health records across thousands of organizations, helping researchers and pharmaceutical developers access real-world data while protecting patient privacy. By structuring data for trial design and interpretation, the company aims to improve clinical outcomes and accelerate medical research.

Syndesi Therapeutics

Series A in 2020
Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.

V-Wave

Series C in 2020
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

XWPharma

Series C in 2020
XWPharma is a biotechnology company based in the Bay Area, California, focused on developing novel therapeutics for underserved central nervous system (CNS) disorders. Their primary areas of interest include sleep disorders like insomnia and neuropsychiatric conditions. The company specializes in drug discovery to address these neglected illnesses, aiming to improve patients' lives by enabling them to overcome sleep-related challenges and lead healthier lives.

Sunday2Sunday

Seed Round in 2020
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.

Aetion

Series B in 2020
Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

G.I. Windows

Series A in 2020
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

ImmPACT Bio

Series A in 2020
ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Thirty Madison

Series B in 2020
Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

Vor Biopharma

Series B in 2020
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

Cue

Series C in 2020
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

HistoSonics

Series C in 2020
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Gatt

Series B in 2020
GATT Technologies BV, established in 2011 and headquartered in Nijmegen, the Netherlands, specializes in developing innovative medical devices. The company focuses on creating synthetic surgical hemostat and sealant products designed to control severe bleeding and organ leakages during surgical procedures. Their product portfolio includes GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, an adhesive tape for preventing intestinal anastomotic leakage; GATT-Spray, an elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. These products are based on a patented synthetic technology, aiming to address challenging surgical bleeding and leakage issues.

RefleXion Medical

Series D in 2020
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

OrthoSpin

Series B in 2020
OrthoSpin Limited is a medical technology company based in Misgav, Israel, founded in 2014. It specializes in the development of innovative robotic external fixation systems designed to enhance patient treatment for bone injuries and limb deformities. The company's dynamic external fixators aim to address the challenges associated with traditional systems, which can be cumbersome and painful while requiring significant maintenance. OrthoSpin's proprietary technology incorporates a lightweight motor and a control box that facilitate automatic, continuous adjustments to the fixation frame without patient involvement. This smart system not only helps ensure that prescribed treatment protocols are followed but also allows physicians to monitor patient progress in real-time and make necessary adjustments to treatment plans. The company's focus on improving clinical outcomes and reducing complications positions it as a significant player in the orthopedic field.

AviadoBio

Seed Round in 2020
AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Mauna Kea Technologies

Post in 2019
Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of advanced imaging technology for the diagnosis and treatment of cancers and other diseases. Founded in 2000, the company focuses on real-time in vivo microscopic visualization to eliminate uncertainties in medical diagnoses. Its primary product, Cellvizio, is a multidisciplinary confocal laser endomicroscopy platform that enables physicians to obtain cellular-level images of tissues during standard medical procedures. Cellvizio has received regulatory approval for use in the United States and over 40 other countries, supporting a wide range of applications. Mauna Kea Technologies generates revenue through the sale of Cellvizio devices, accessories, and related services, while emphasizing its role in enhancing diagnostic accuracy and informing therapeutic decisions.

ProteKt Therapeutics

Venture Round in 2019
ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR, targeting neurodegenerative and neuroinflammatory diseases. The company utilizes unique computational methods to develop a series of novel and selective molecules, which are validated through clinically relevant assays. This approach aims to address issues such as memory consolidation impairment and enhance long-term memory in patients. In 2019, ProteKt Therapeutics graduated from the FutuRx accelerator and subsequently raised $4 million in a pre-A funding round to support its innovative research and development efforts.

X-Vax

Series A in 2019
X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.

Cara Care

Series A in 2019
Cara Care is a digital health platform focused on improving gut health for individuals with chronic gastrointestinal issues. It offers an app that enables patients to track their dietary habits, symptoms, and emotional states, facilitating a better understanding of their digestive health. By combining behavioral, microbial, and nutritional data, Cara Care empowers over 700,000 patients worldwide to take control of their health. The application allows users to customize their food choices and monitor symptoms such as pain and bloating, helping them identify patterns related to their conditions. This innovative approach goes beyond traditional treatment methods, providing a comprehensive tool for managing chronic digestive disorders in a convenient manner.

Blackthorn Therapeutics

Series B in 2019
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

TechsoMed

Venture Round in 2019
TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Cala Health

Series C in 2019
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Fusion Pharmaceuticals

Series B in 2019
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Hamilton, Canada, specializing in the development of next-generation radiopharmaceuticals as precision medicines for challenging cancers. The company leverages its Targeted Alpha Therapies platform and proprietary Fast-Clear linker technology to connect alpha particle-emitting isotopes with antibodies and other targeting molecules, enabling selective delivery of cytotoxic payloads to tumors. Its lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, Fusion is conducting preclinical studies to explore the combination of FPI-1434 with approved checkpoint inhibitors and DNA damage response inhibitors to enhance anti-tumor activity. The company is also advancing FPI-1966, aimed at treating head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014, Fusion Pharmaceuticals aims to innovate within the field of radiopharmaceuticals, transforming internalizing antibodies into effective cytotoxic drugs for improved cancer treatment outcomes.

Vor Biopharma

Series A in 2019
Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

Memebox

Series D in 2019
Memebox Corporation is an online retailer specializing in beauty care products, with a strong emphasis on Asian beauty trends, particularly K-beauty. Founded in 2012 and headquartered in San Francisco, California, the company offers a wide range of skincare and makeup items. Its skincare selection includes cleansers, toners, masks, serums, creams, and various body care products. In addition, Memebox provides an extensive array of makeup products such as foundations, concealers, eyeshadows, lip care items, and nail care products. The company serves a diverse customer base across the United States, China, Korea, and other international markets, aiming to deliver products that reflect the latest beauty trends and cultural influences.

Ribon Therapeutics

Series B in 2019
Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

MultiScale Health Networks

Venture Round in 2018
MultiScale Health Networks LLC is a Seattle-based company that specializes in developing and marketing a cloud-based data platform designed for the healthcare industry. Established in 2012, the company focuses on providing real-time data access to enhance operational intelligence within healthcare settings, particularly in emergency departments. Their platform, known as MultiScale Hive, enables the extraction, aggregation, and optimization of critical patient data, facilitating communication and collaboration among multidisciplinary teams. By leveraging technologies such as data mining and machine learning, MultiScale Health Networks aims to improve care delivery outcomes, enhance patient engagement, and increase operational efficiency, ultimately transforming healthcare into a more responsive system.

Carrot

Venture Round in 2018
Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot provides a unique six-stage program that engages smokers at an early stage, fostering awareness and confidence without pressuring them to quit. The application assists users in identifying their motivations for quitting and guides them in developing a personalized quit plan. For those ready to make a change, Pivot offers one-on-one coaching support, helping individuals execute their plans and maintain stability in their cessation journey. Through this approach, Carrot aims to support smokers in their transition away from tobacco use.

CuraSen Therapeutics

Series A in 2018
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

PhaseBio

Series D in 2018
PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

OrthoSpin

Venture Round in 2018
OrthoSpin Limited is a medical technology company based in Misgav, Israel, founded in 2014. It specializes in the development of innovative robotic external fixation systems designed to enhance patient treatment for bone injuries and limb deformities. The company's dynamic external fixators aim to address the challenges associated with traditional systems, which can be cumbersome and painful while requiring significant maintenance. OrthoSpin's proprietary technology incorporates a lightweight motor and a control box that facilitate automatic, continuous adjustments to the fixation frame without patient involvement. This smart system not only helps ensure that prescribed treatment protocols are followed but also allows physicians to monitor patient progress in real-time and make necessary adjustments to treatment plans. The company's focus on improving clinical outcomes and reducing complications positions it as a significant player in the orthopedic field.

S-Biomedic

Series A in 2018
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics that target the skin microbiome. Based in Beerse, the company develops innovative skincare solutions aimed at addressing various skin conditions such as acne, eczema, rosacea, and signs of aging. By employing a targeted modulation-based technology, S-Biomedic selects and combines beneficial bacteria to rebalance the skin’s microbiome, thus restoring its health. Their products are formulated using advanced microbiological and dermatological research, allowing them to effectively contribute to skin health and beauty. Through their novel approach, S-Biomedic offers a new class of therapeutic options for both dermatological and cosmetic applications.

Zebra Medical Vision

Series C in 2018
Zebra Medical Vision Ltd. is a developer of an advanced imaging analytics platform that enhances the capabilities of healthcare institutions in diagnosing and managing diseases. Founded in 2014 and based in Shefayim, Israel, the company provides clinicians with tools for identifying patients at risk of various conditions and facilitates improved preventative treatment pathways. Its platform features advanced learning and computer vision diagnostic algorithms, catering to both healthcare providers and machine-learning researchers. Zebra Medical Vision has established strategic collaborations with organizations such as USARAD Holdings and TELUS Ventures, and its products have received FDA clearance for use in hospitals worldwide, including locations in Australia, India, Europe, the U.S., and Latin America. The company is recognized for its role in the AI and machine learning landscape, having raised significant funding to support its innovative solutions in medical imaging.

NeuroVision

Series C in 2018
NeuroVision Imaging LLC, established in 2010 and based in Sacramento, California, specializes in developing digital imaging and diagnostic solutions for Alzheimer's disease and eye care markets. The company's core focus is the development of diagnostic tests and biomarkers for the early detection and monitoring of amyloid pathology related to Alzheimer's disease. NeuroVision has pioneered a retinal imaging technology that uses low-cost, non-invasive eye imaging to measure retinal autofluorescence, aiming to assess the accumulation of amyloid-beta plaque in the brain. Additionally, the company offers data aggregation services, analysis, biostatistics, and machine learning algorithms to analyze large repositories of images and other biomarker data, furthering the understanding and prediction capabilities for neurodegenerative diseases. NeuroVision serves clients in the United States and internationally.

Syndesi Therapeutics

Series A in 2018
Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.

On Target Laboratories

Series B in 2017
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.